EUVIMEDEUVIMED entdecken
Crossref

Feasibility of targeted alpha therapy for Alzheimer’s disease using 211At-labeled agent targeting amyloid-β aggregates

Rikuto Kashiyama, Hiroyuki Watanabe, Takahiro Akasaka, Hiroyuki Fujimoto, Masashi Murakami, Kazuhiro Ooe, Atsushi Toyoshima, Kazuma Nakashima, Masahiro Ono

Annals of Nuclear Medicine · 2025

DOI: 10.1007/s12149-025-02095-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Rikuto Kashiyama und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-cho, Sakyo-ku, K…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Alpha Particles, Protein Aggregates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Amyloid-β (Aβ) aggregates have been recognized as therapeutic targets for Alzheimer's disease (AD). Targeted alpha therapy (TAT) using α-particles has the potential to be applied as a novel treatment approach for AD by reducing the quantity of Aβ aggregates. In this study, we developed a novel astatine-211-labeled pyridyl benzofuran (PBF) derivative, [211At]APBF-2, as a small molecule-based Aβ-TAT agent and evaluated its potential for in vivo use. METHODS: [211At]APBF-2 was synthesized in a one-step astatination process using the tributyltin precursor. In the Aβ aggregation inhibition assay, [211At]APBF-2 was added to a sample containing Aβ1-42 monomers and thioflavin-T (ThT) and the mixture was incubated for 24 h. The quantity of Aβ aggregates was evaluated by measuring ThT fluorescence intensity. The biodistribution of [211At]APBF-2 (25 kBq/100 μL) was evaluated using ddY mice (n = 5). RESULTS: [211At]APBF-2 was synthesized in radiochemical yield of 57% with a radiochemical purity of over 95%. In the in vitro assay, [211At]APBF-2 showed a dose-dependent decrease in ThT fluorescence intensity, suggesting the ability of [211At]APBF-2 to inhibit Aβ aggregation. In the biodistribution study using normal mice, the initial brain uptake of [211At]APBF-2 was observed (2.95% injected dose/g at 2 min), demonstrating favorable Blood-brain barrier permeability. CONCLUSIONS: These results suggest the feasibility of using [211At]APBF-2 as an Aβ-TAT agent for in vivo applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesAlpha ParticlesProtein AggregatesMolecular Targeted TherapyAnimalsMiceFeasibility StudiesTissue DistributionBenzofuransHumansMaleIsotope Labeling

Stichwörter der Autor:innen

Amyloid-β (Aβ)Astatine-211 (211At)Blood–brain barrier permeabilityPyridyl benzofuran (PBF)Targeted alpha therapy (TAT)

Substanzen

Amyloid beta-PeptidesProtein AggregatesBenzofurans

Autor:innen und Institutionen

  • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
  • Radioisotope Research Center, Agency for Health, Safety and Environment, Kyoto University, Kyoto, 606-8501, Japan.
  • Institute for Radiation Sciences, Osaka University, 2-4, Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan. ono@pharm.kyoto-u.ac.jp.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Kashiyama, R., Watanabe, H., Akasaka, T., Fujimoto, H., Murakami, M., Ooe, K., Toyoshima, A., Nakashima, K., & Ono, M. (2025). Feasibility of targeted alpha therapy for Alzheimer’s disease using 211At-labeled agent targeting amyloid-β aggregates. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02095-8

Vancouver

Kashiyama R, Watanabe H, Akasaka T, Fujimoto H, Murakami M, Ooe K, et al. Feasibility of targeted alpha therapy for Alzheimer’s disease using 211At-labeled agent targeting amyloid-β aggregates. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-025-02095-8

BibTeX
@article{Kashiyama2025,
  author = {Kashiyama, Rikuto and Watanabe, Hiroyuki and Akasaka, Takahiro and Fujimoto, Hiroyuki and Murakami, Masashi and Ooe, Kazuhiro and Toyoshima, Atsushi and Nakashima, Kazuma and Ono, Masahiro},
  title = {Feasibility of targeted alpha therapy for Alzheimer’s disease using 211At-labeled agent targeting amyloid-β aggregates},
  journal = {Annals of Nuclear Medicine},
  year = {2025},
  doi = {10.1007/s12149-025-02095-8}
}
Kostenlos starten →